Penumbra's sales rose 15.6%, both product areas grew, and it reported $42.3 million in net income. This points to a stronger business despite $7.1 million in deal costs and no 2026 forecast.
Growth in both product areas, along with reported profit, points to a stronger business. Penumbra also reported costs tied to its pending Boston Scientific deal. It gave no full-year forecast and held no results call, leaving less information about the coming year.
The report says Penumbra's acquisition by Boston Scientific is pending. It gives no new results or deal terms for Boston Scientific, so it does not change the company's outlook.
Follow Penumbra, Inc. (PEN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PEN